EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase IV)Open Access · CC BY-NC 4.0

Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial

Cüneyt Arikan iD, Pınar Yeşim Akyol iD

Science Progress · 2024

DOI: 10.1177/00368504241264993 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift Science Progress, 2024. Verfasst von Cüneyt Arikan und 1 weiteren Autor:innen. Beteiligte Einrichtung: Department of Emergency Medicine, İzmir Ataturk Training and Research Hospital, Izmir, Turkey. Hauptthemen laut MEDLINE: Tranexamic Acid, Epistaxis, Administration, Topical, Antifibrinolytic Agents. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 17 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Patients with epistaxis typically visit the emergency department for initial treatment. According to recent studies, tranexamic acid (TXA) is effective in the treatment of epistaxis. This study compared the therapeutic superiority of saline to that of 500 and 1000 mg doses of topical TXA for the treatment of anterior epistaxis. Materials and methods: This phase 4 clinical trial was a randomized, controlled, and double-blind trial. A total of 152 patients were divided into three groups. Group 1 was treated with 1000 mg TXA, Group 2 with 500 mg TXA, and Group 3 with saline.

Results

Based on multinomial logistic regression analysis, the bleeding frequency at the 5th minute was 2.9 times and rebleeding status was 4.3 times less in Group 1 (1000 mg TXA) than in Group 3 (saline). There were no differences between the three groups in terms of side effects or salvage therapy.

Conclusion

In addition to its superiority in treatment, 1000 mg of TXA is recommended because of the decreased rate of recurrent bleeding and low incidence of side effects.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Tranexamic AcidEpistaxisAdministration, TopicalAntifibrinolytic AgentsHumansDouble-Blind MethodMaleFemaleMiddle AgedAdultAgedTreatment OutcomeDose-Response Relationship, Drug

Stichwörter der Autor:innen

Anterior epistaxisemergency medicinetopicaltranexamic acidtreatment

Substanzen

Tranexamic AcidAntifibrinolytic Agents

Autor:innen und Institutionen

  • Department of Emergency Medicine, İzmir Ataturk Training and Research Hospital, Izmir, Turkey.
  • Department of Emergency Medicine, Soma State Hospital, Manisa, Turkey.

ORCID-Profile: Cüneyt Arikan, Pınar Yeşim Akyol

Zitieren

APA

Arikan, C., & Akyol, P. Y. (2024). Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial. Science Progress. https://doi.org/10.1177/00368504241264993

Vancouver

Arikan C, Akyol PY. Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial. Science Progress. 2024. doi:10.1177/00368504241264993

BibTeX
@article{Arikan2024,
  author = {Arikan, Cüneyt and Akyol, Pınar Yeşim},
  title = {Appropriate dose of tranexamic acid in the topical treatment of anterior epistaxis, 500 mg vs 1000 mg: A double-blind randomized controlled trial},
  journal = {Science Progress},
  year = {2024},
  doi = {10.1177/00368504241264993}
}
Kostenlos starten →